GoodRx Holdings (GDRX)
Nasdaq Market Closed
GoodRx Holdings, Inc. operates a US digital healthcare platform built around prescription affordability and consumer access. The company is best known for its price comparison tools, which allow users to search for prescription drugs, compare cash prices at nearby pharmacies, and use GoodRx codes or coupons to access negotiated discounts. Its services are designed for consumers facing high out-of-pocket costs, including people without insurance, those with high-deductible plans, or patients whose medication is not covered favorably by an insurance formulary.
GoodRx’s core business is tied to prescription transactions. When a consumer uses a GoodRx code at a pharmacy, the company typically earns fees from pharmacy benefit managers and related partners that participate in the pricing and claims-processing network. This model places GoodRx between consumers, pharmacies, and drug-pricing intermediaries, with the platform aiming to make prescription pricing more transparent and competitive.
Beyond its coupon marketplace, GoodRx offers additional healthcare products and services. These include subscription programs such as GoodRx Gold, manufacturer solutions that help pharmaceutical companies engage patients and providers, and telehealth-related services that connect consumers with healthcare professionals for certain conditions. The company also publishes healthcare information designed to help users understand medications, treatment options, and insurance-related costs.
As a listed company, GoodRx is exposed to changes in the US healthcare system, prescription volumes, pharmacy benefit manager relationships, consumer demand, and competition from insurers, pharmacies, drug manufacturers, and other digital health platforms. Its distinctive position is its consumer-facing brand in a complex prescription market where pricing can vary widely by location and payment method.
Last updated
- Market Cap
- 999.09M
- P/E
- 48.6
- P/FCF
- 8.54
- P/S
- 1.27
- Enterprise Value
- 1.25B
- Sector
- Industrials
- Industry
- Computer Processing and Data Preparation and Processing Services
- Address
- 2701 OLYMPIC BOULEVARD, SANTA MONICA, CA, 90404
Telepharmacy Market Size to Reach US$ 21.89 Billion By 2032, Bridges Rural–Urban Healthcare Gap and Expands Digital Pharmacy Access | S&S Insider
More Zero-cost Virtual Healthcare Appointments Available to Those Affected by Wildfires in Southern California
RBC holds firm on GoodRx stock target with Outperform rating - Investing.com
Wall Street Breakfast: The Week Ahead
GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
ELV vs. GDRX: Which Stock Is the Better Value Option?
ELV or GDRX: Which Is the Better Value Stock Right Now?
Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know
Encompass Health (EHC), Piedmont to Build Loganville Facility
ELV or GDRX: Which Is the Better Value Stock Right Now?
Can GoodRx Holdings, Inc. (GDRX) Run Higher on Rising Earnings Estimates?
GoodRx Holdings, Inc. (GDRX) is a Great Momentum Stock: Should You Buy?
GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates
Agiliti (AGTI) Expected to Beat Earnings Estimates: Should You Buy?
What to Look for in Crescent Point's (CPG) Q4 Earnings?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 999.09M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 1.25B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 48.6
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.61
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.27
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 7.62
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.59
- EPS
- 0.06
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 8.54
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 5.87
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 117.05M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 3.3%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 1.02%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.78
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.47
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.47
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.27
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.75M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.95
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 194.01M | 194.79M | 196.03M | 203.07M | 202.97M |
| Gross profit | 173.85M | 177.32M | 182.61M | 189.72M | 189.61M |
| Operating income | 14.01M | 22.68M | 14.62M | 26.81M | 23.38M |
| EBITDA | 35.8M | 45.83M | 36.05M | 46.54M | 44.29M |
| Net income | 1.17M | 5.43M | 1.12M | 12.84M | 11.05M |
| Basic EPS | — | 0.02 | — | 0.04 | 0.03 |
| Diluted EPS | — | 0.02 | — | 0.04 | 0.03 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 2.02B | 1.4B | 1.33B | 1.32B | 1.3B |
| Total liabilities | 1.4B | 787.8M | 724.8M | 675.68M | 640.92M |
| Total equity | 621.99M | 616.26M | 600.71M | 643.03M | 654.35M |
| Cash & equivalents | 235.71M | 261.82M | 273.53M | 281.32M | 300.98M |
| Current assets | 1.27B | 643.1M | 565.52M | 550.61M | 540.21M |
| Current liabilities | 859.2M | 246M | 181.86M | 130.91M | 103.38M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 11.84M | 32.89M | 76.02M | 49.58M | 9.41M |
| Investing cash flow | -21.64M | -31.77M | -18M | -18.32M | -51.88M |
| Financing cash flow | -16.3M | -12.83M | -65.81M | -50.93M | -104.9M |
| Change in cash | -26.11M | -11.71M | -7.79M | -19.66M | -147.37M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| edgar index | 144 — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| form 4 | Form 4 — Chan Thomas (TC) | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 10-Q — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — GoodRx Holdings, Inc. | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| form 3 | Form 3 — Chan Thomas (TC) | View Filing | |
| edgar index | DEF 14A — GoodRx Holdings, Inc. | View Filing | |
| edgar index | DEFA14A — GoodRx Holdings, Inc. | View Filing | |
| edgar index | ARS — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — Barnes Wendy Lynn | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| form 4 | Form 4 — McGinnis Christopher A | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — GoodRx Holdings, Inc. | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| form 4 | Form 4 — REY-GIRAUD AGNES | View Filing | |
| form 4 | Form 4 — REY-GIRAUD AGNES | View Filing | |
| form 4 | Form 4 — REY-GIRAUD AGNES | View Filing | |
| form 4 | Form 4 — REY-GIRAUD AGNES | View Filing | |
| edgar index | 4 — GoodRx Holdings, Inc. | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| form 4 | Form 4 — Nabiey Romin | View Filing | |
| edgar index | 8-K — GoodRx Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing |